Replek AD Skopje

Replek AD Skopje has a capital structure with 259,200 basic and diluted shares outstanding, indicating no dilution pressure from share-based compensation or convertible instruments. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents. The company reported a gross profit of MKD 198.78 million and an operating income of MKD 31.45 million, translating to a gross margin of 51.25% and an operating margin of 8.11%. These figures are consistent with industry norms for pharmaceutical firms, which typically maintain high gross margins due to the capital-intensive nature of R&D and production. Geographically, Replek's revenue is concentrated in the Balkans and Eastern Europe, with no disclosed segment breakdown. This regional concentration may expose the company to regulatory and economic volatility in these markets, particularly in light of geopolitical tensions in the region. Looking ahead, the company's growth trajectory is constrained by limited financial disclosure. While the current fiscal year's revenue of MKD 387.91 million provides a baseline, there are no disclosed projections for the next fiscal year. The absence of detailed guidance limits visibility into future performance. Risk factors include the inability to assess liquidity risk and the lack of detailed financial disclosures. The company has not issued any recent public filings or transcripts that would clarify its capital structure or strategic direction. Recent events include the absence of notable filings or transcripts, which limits the ability to assess management's strategic direction or financial health. The company has not issued any public statements or guidance that would indicate a shift in business strategy or financial outlook.